| 1 |
Marteau P, Probert CS, Lindgren S, et al.Combined oral and enema treatment with Pentasa(mesalazine)is superior to oral therapy alone in patients with extensive mild/moderate activeulcerative colitis: a randomised, double blind, placebo controlled study[J]. Gut, 2005, 54(7): 960-965.
|
| 2 |
D′Albasio G, Pacini F, Camarri E, et al.Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study[J]. Am J Gastroenterol, 1997, 92(7): 1143-1147.
|
| 3 |
Malchow H, Ewe K, Brandes JW, et al.European Cooperative Crohn′s Disease Study(ECCDS): results of drug treatment[J]. Gastroenterology, 1984, 86(2): 249-266.
|
| 4 |
Blaker PA, Arenas-Hernandez M, Smith MA, et al.Mechanism of allopurinol induced TPMT inhibition[J]. Biochem Pharmacol, 2013, 86(4): 539-547.
|
| 5 |
Smith MA, Blaker P, Marinaki AM, et al.Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol[J]. J Crohns Colitis, 2012, 6(9): 905-912.
|
| 6 |
Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy[J]. Eur J Gastroenterol Hepatol, 2001, 13(11): 1297-1301.
|
| 7 |
Mantzaris GJ, Sfakianakis M, Archavlis E, et al.A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis[J]. Am J Gastroenterol, 2004, 99(6): 1122-1128.
|
| 8 |
Mate-Jimenez J, Hermida C, Cantero-Perona J, et al.6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease[J]. Eur J Gastroenterol Hepatol, 2000, 12(11): 1227-1233.
|
| 9 |
Ewe K, Press AG, Singe CC, Stufler M, et al.Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn′s disease[J]. Gastroenterology, 1993, 105(2): 367-372.
|
| 10 |
Vasudevan A, Raghunath A, Anthony S, et al.Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn′s Disease[J]. Dig Dis Sci, 2019, 64(6): 1622-1631.
|
| 11 |
Panaccione R, Ghosh S, Middleton S, et al.Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis[J]. Gastroenterology, 2014, 146(2): 392-400.e3.
|
| 12 |
Kopylov U, Al-Taweel T, Yaghoobi M, et al.Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn′s disease: a systematic review and meta-analysis[J]. J Crohns Colitis, 2014, 8(12): 1632-1641.
|
| 13 |
Feagan BG, McDonald JW, Panaccione R, et al.Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn′s disease[J]. Gastroenterology, 2014, 146(3): 681-688.e1.
|
| 14 |
Colman RJ, Rubin DT.Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease[J]. J Crohns Colitis, 2015, 9(2): 312-317.
|
| 15 |
Cortes X, Borras-Blasco J, Fernendez S, et al.Successful use of infliximab and tacrolimus combination therapy in a patient with ulcerative colitis refractory to infliximab dose intensification plus azathioprine[J]. Int J Clin Pharmacol Ther, 2016, 54(2): 125-128.
|
| 16 |
Bots S, Gecse K, Barclay M, et al.Combination Immunosuppression in IBD[J]. Inflamm Bowel Dis, 2018, 24(3): 539-545.
|
| 17 |
Lowry PW, Weaver AL, Tremaine WJ, et al.Combination therapy with oral ta-crolimus(FK506)and azathioprine or 6-mer-captopurine for treatment-refractory Crohn′s disease perianal fistulae[J]. Inflamm Bowel Dis, 1999, 5(2): 239-245.
|
| 18 |
Tanida S, Mizoshita T, Nishie H, et al.Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis[J]. J Clin Med Res, 2015, 7(11): 884-889.
|
| 19 |
Chi LY, Zitomersky NL, Liu E, et al.The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease[J]. Inflamm Bowel Dis, 2018, 24(6): 1344-1351.
|
| 20 |
Colombel JF, Sandborn WJ, Panaccione R, et al.Adalimumab safety in global clinical trials of patients with Crohn′s disease[J]. Inflamm Bowel Dis, 2009, 15(9): 1308-1319.
|
| 21 |
Singh S, Facciorusso A, Dulai PS, et al.Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis[J]. Clin Gastroenterol Hepatol, 2019, S1542-3565(19)30255-1.
|
| 22 |
Deepak P, Sifuentes H, Sherid M, et al.T-cell non-Hodg-kin′s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha(TNF-α)in-hibitors: results of the REFURBISH study[J]. Am J Gastroenterol, 2013, 108(1): 99-105.
|
| 23 |
Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor ne-crosis factor alpha therapy for treatment of Crohn′s disease[J]. Expert Opin Drug Saf, 2016, 15(4): 493-501.
|